Massively parallel AST

BacterOMIC provides fastest access to complete information to direct targeted antibiotic therapies.

BacterOmic delivers complete information on phenotypic antibiotic susceptibility of bacterial pathogens: MIC values for all antibiotics and synergies between up to 20 combinations. It enables precision therapies already after the first test.

BacterOMIC provides MIC values for 2.5-10 times more agents than competitors, eliminating the need of additional testing, reducing cost and time.

  • Antimicrobial stewardship
  • Microbial diagnostics
  • Infection prevention
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Development
  • Research
  • Validation
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • Co-develop
  • Joint Venture
  • Sell
  • License
  • Outsource

Funding organisation:

    Infectious disease area:

      Geographic origin:

        We seek strategic partnership with a global diagnostic systems supplier that can best leverage the market value of Bacteromic, offering complete AST information for targeted antibiotics therapies, within established workflow and test-price structure.

        BacterOmic is a med-tech startup developing automated AST to provide doctors MIC values for all clinically relevant antibiotics from a single test

        BacterOmic is part of Scope Fluidics Group, that develops also point-of-care molecular Dx system – PCR|ONE featuring 15-minute time-to-result and high multiplexing capacity. The first PCR|ONE panel detects and characterizes MRSA infections.

        What is going on with AMR?
        Stay tuned with remarkable global AMR news and developments!